MétaCan
Menu
← Back to cohort
Record W4205246393 · doi:10.2196/preprints.26718

Clinical Trial Data Sharing for COVID-19–Related Research (Preprint)

2020· preprint· en· W4205246393 on OpenAlexaff
Louis Dron, Alison Dillman, Michael J. Zoratti, Jonas Häggström, Edward J. Mills, Jay Park

Bibliographic record

Venuenot available
Typepreprint
Languageen
FieldMedicine
TopicCOVID-19 and healthcare impacts
Canadian institutionsMcMaster UniversityUniversity of British ColumbiaImpact
Fundersnot available
KeywordsSample size determinationContext (archaeology)Statistical powerClinical trialCoronavirus disease 2019 (COVID-19)PandemicSample (material)Data sharingPerspective (graphical)PsychologyMedicineComputer scienceStatisticsAlternative medicineGeographyMathematicsArtificial intelligence

Abstract

fetched live from OpenAlex

UNSTRUCTURED This paper aims to provide a perspective on data sharing practices in the context of the COVID-19 pandemic. The scientific community has made several important inroads in the fight against COVID-19, and there are over 2500 clinical trials registered globally. Within the context of the rapidly changing pandemic, we are seeing a large number of trials conducted without results being made available. It is likely that a plethora of trials have stopped early, not for statistical reasons but due to lack of feasibility. Trials stopped early for feasibility are, by definition, statistically underpowered and thereby prone to inconclusive findings. Statistical power is not necessarily linear with the total sample size, and even small reductions in patient numbers or events can have a substantial impact on the research outcomes. Given the profusion of clinical trials investigating identical or similar treatments across different geographical and clinical contexts, one must also consider that the likelihood of a substantial number of false-positive and false-negative trials, emerging with the increasing overall number of trials, adds to public perceptions of uncertainty. This issue is complicated further by the evolving nature of the pandemic, wherein baseline assumptions on control group risk factors used to develop sample size calculations are far more challenging than those in the case of well-documented diseases. The standard answer to these challenges during nonpandemic settings is to assess each trial for statistical power and risk-of-bias and then pool the reported aggregated results using meta-analytic approaches. This solution simply will not suffice for COVID-19. Even with random-effects meta-analysis models, it will be difficult to adjust for the heterogeneity of different trials with aggregated reported data alone, especially given the absence of common data standards and outcome measures. To date, several groups have proposed structures and partnerships for data sharing. As COVID-19 has forced reconsideration of policies, processes, and interests, this is the time to advance scientific cooperation and shift the clinical research enterprise toward a data-sharing culture to maximize our response in the service of public health.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.196
metaresearch head score (Gemma)0.573
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Open science
Consensus categoriesMetaresearch
DomainCandidate signal: Reproducibility · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.996
Threshold uncertainty score0.992

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.1960.573
Meta-epidemiology (narrow)0.0010.003
Meta-epidemiology (broad)0.0030.005
Bibliometrics0.0080.013
Science and technology studies0.0020.004
Scholarly communication0.0190.008
Open science0.0040.011
Research integrity0.0080.007
Insufficient payload (model declined to judge)0.2500.136

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.889
GPT teacher head0.699
Teacher spread0.191 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; the direct Gemma label and the distilled Codex classifier agree on what is shown here.

Study designNot applicable
DomainReproducibility
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2020
Admission routes1
Has abstractyes

Explore more

Same topicCOVID-19 and healthcare impacts→French-language works237,207→